<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03566225</url>
  </required_header>
  <id_info>
    <org_study_id>AinShamaU</org_study_id>
    <nct_id>NCT03566225</nct_id>
  </id_info>
  <brief_title>Pioglitazone Versus Metformin as First Treatment in Infertile Women With Polycystic Ovary Syndrome</brief_title>
  <official_title>Combined Pioglitazone and Clomophene Citrate Versus Combined Metformin and Clomiphene Citrate as First Treatment in Infertile Women With Polycystic Ovary Syndrome</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ain Shams University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ain Shams University</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Participants with PCOS will be divided into two groups then each group will randomly recieve
      one of the following treatment

        1. metformin will be adminstered in adose of 500 mg 3 times daily for 3 months to group B.

        2. pioglitazone will be administered in adose of 30 mg dialy for 3 months to group A.

        3. Induction of ovulation by clomiphene citate 50 mg tablets to all participants
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Participants with PCOS will be divided into two groups then each group will randomly recieve
      one of the following treatment

        1. metformin will be adminstered in adose of 500 mg 3 times daily for 3 months to group B.

        2. pioglitazone will be administered in adose of 30 mg dialy for 3 months to group A.

        3. Induction of ovulation by clomiphene citate 50 mg tablets once or twice dialy 12hours
           apart starting from the 3rd day of menstrual cycle and continue for five days during
           treatment with insulin sensitizing agents to group A and B.

      Participants with oligomenorrhea will recieve two tablets of noreththisterone 5 mg tab every
      12 hours for 5 days to allow for withdrawal bleeding before start ovulation induction
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 30, 2018</start_date>
  <completion_date type="Anticipated">May 25, 2019</completion_date>
  <primary_completion_date type="Anticipated">April 25, 2019</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Clinical pregnancy rate</measure>
    <time_frame>3 months</time_frame>
    <description>Pregnancy rate diagnosed by U/S at five weeks after missed menses</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">400</enrollment>
  <condition>Pioglitazone</condition>
  <arm_group>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Pioglitazone in adose 30 mg tablet will be administered dialy+ clomiphene citrate as ovulation induction</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Metformin in adose 1500 mg dialy will be administered + clomiphene citrate</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pioglitazone</intervention_name>
    <description>Insulin sensitizing agents</description>
    <arm_group_label>Group A</arm_group_label>
    <other_name>Glustazon</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Metformin</intervention_name>
    <description>Insulin sensitizing agent</description>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Cidophage</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Clomiphene Citrate</intervention_name>
    <description>Induction drug</description>
    <arm_group_label>Group A</arm_group_label>
    <arm_group_label>Group B</arm_group_label>
    <other_name>Clomid</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  women age 20_35

          -  BMI 18_29.9

          -  Women with PCOS(diagnosed by using Rotterdam criteria

          -  Infertility is cause for seeking tfeatment

        Exclusion Criteria:

          -  Causes of infertility other than PCOS.

          -  patient refusal.

          -  Contraindication of any of the drugs used in the study

          -  Cause of oligo/anovulation other than PCOS

          -  Current or previous (within the last six month) use of oral contraceptives,
             glucocorticoids, antiandrogens, antidiabetics, antiobesity drugs or other hormonal
             drugs.
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Asmaa Salih, Resident</last_name>
    <role>Principal Investigator</role>
    <affiliation>AinShams University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ain Shams Univerisity</name>
      <address>
        <city>Cairo</city>
        <country>Egypt</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>May 26, 2018</study_first_submitted>
  <study_first_submitted_qc>June 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">June 25, 2018</study_first_posted>
  <last_update_submitted>February 14, 2019</last_update_submitted>
  <last_update_submitted_qc>February 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Ain Shams University</investigator_affiliation>
    <investigator_full_name>Asmaa Abdelbadea Ali Salih</investigator_full_name>
    <investigator_title>Cairo</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Polycystic Ovary Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metformin</mesh_term>
    <mesh_term>Pioglitazone</mesh_term>
    <mesh_term>Clomiphene</mesh_term>
    <mesh_term>Enclomiphene</mesh_term>
    <mesh_term>Zuclomiphene</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

